Yarrow Bioscience
YARW
98 hedge funds and large institutions have $160M invested in Yarrow Bioscience in 2020 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 53 increasing their positions, 7 reducing their positions, and 21 closing their positions.
657% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 7
73% more capital invested
Capital invested by funds: $92.7M → $160M (+$67.5M)
57% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 21
24.64% more ownership
Funds ownership: 25.45% → 50.09% (+25%)
14% more funds holding
Funds holding: 86 → 98 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$30.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$12.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.3M |
| 4 |
BlackRock
New York
|
+$9.88M |
| 5 |
6CM
683 Capital Management
New York
|
+$6.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.43M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$3.92M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$2.83M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.68M |
| 5 |
O
OrbiMed
New York
|
-$2.17M |
YARW Hedge Fund Activity: Q2 2020 in Review
98 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2020, worth a combined $160M — up 73% from $92.7M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new YARW positions and 21 closed out — a net gain of 12 holders — while 53 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $30.5M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.43M sold.
- 98 institutional investors held Yarrow Bioscience (YARW) as of Q2 2020, up from 86 in Q1 2020.
- Funds reported $160M of Yarrow Bioscience stock for Q2 2020, up 73% quarter-over-quarter.
- 33 funds opened new Yarrow Bioscience positions in Q2 2020 and 21 closed out, a net change of +12 holders.
- The largest Yarrow Bioscience buyer in Q2 2020 was Perceptive Advisors, an estimated $30.5M added.
- The largest Yarrow Bioscience seller in Q2 2020 was Great Point Partners, an estimated $4.43M sold.
Based on aggregated 13F filings for Q2 2020.